Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | APOB | P04114 | 6/20 | 0.37 |
| ▸ | MTTP | P55157 | 6/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795031 | 0.90 | SMO (0.40) | SMOALDH1A1F2KDM4EGAA | |
| SCHEMBL6795768 | 0.89 | SMO (0.45) | SMOUGCGALDH1A1GAAHCRTR1 | |
| SCHEMBL6795028 | 0.85 | BACE1 (0.41) | SMOALDH1A1F2KDM4EGAA | |
| SCHEMBL6796112 | 0.84 | MEN1 (0.41) | F2TRPV4 | |
| SCHEMBL6792911 | 0.82 | SMO (0.47) | SMOALDH1A1F2KDM4EGAA | |
| SCHEMBL6795007 | 0.82 | SMO (0.48) | SMOALDH1A1F2KDM4EGAA | |
| SCHEMBL6645327 | 0.82 | ALDH1A1 (0.43) | ALDH1A1F2KDM4EGAA | |
| SCHEMBL6648457 | 0.81 | F2 (0.40) | SMOALDH1A1F2L3MBTL1TRPV4 | |
| SCHEMBL6793746 | 0.81 | SMO (0.53) | SMOAPOBMTTP | |
| SCHEMBL6788780 | 0.80 | RAB9A (0.42) | SMOALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885UGCG 903/4885ALDH1A1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.